Market Research Logo

Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015

Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hypogonadotropic Hypogonadism - Pipeline Review, H2 2015’, provides an overview of the Hypogonadotropic Hypogonadism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypogonadotropic Hypogonadism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypogonadotropic Hypogonadism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypogonadotropic Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypogonadotropic Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypogonadotropic Hypogonadism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypogonadotropic Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hypogonadotropic Hypogonadism Overview
Therapeutics Development
Pipeline Products for Hypogonadotropic Hypogonadism - Overview
Pipeline Products for Hypogonadotropic Hypogonadism - Comparative Analysis
Hypogonadotropic Hypogonadism - Therapeutics under Development by Companies
Hypogonadotropic Hypogonadism - Therapeutics under Investigation by Universities/Institutes
Hypogonadotropic Hypogonadism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hypogonadotropic Hypogonadism - Products under Development by Companies
Hypogonadotropic Hypogonadism - Products under Investigation by Universities/Institutes
Hypogonadotropic Hypogonadism - Companies Involved in Therapeutics Development
BIOCAD
Forendo Pharma Oy
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Repros Therapeutics Inc.
Hypogonadotropic Hypogonadism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BGS-649 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enclomiphene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fispemifene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
follitropin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-448 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypogonadotropic Hypogonadism - Recent Pipeline Updates
Hypogonadotropic Hypogonadism - Product Development Milestones
Featured News & Press Releases
Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA
Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application
Apr 06, 2015: Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance
Apr 01, 2015: Repros Announces Acceptance for Filing of NDA
Oct 27, 2014: Repros to Webcast Investor and Analyst Day on October 31st
Oct 21, 2014: Results From Long-Term Study of Androxal Exhibit Positive Safety Profile
Sep 26, 2014: FDA Schedules Type B Pre-NDA Meeting With Repros
Sep 25, 2014: Androxal Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism
Jul 16, 2014: FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal Versus Approved Topical Gel and Placebo
May 13, 2014: Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypogonadotropic Hypogonadism, H2 2015
Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Hypogonadotropic Hypogonadism - Pipeline by BIOCAD, H2 2015
Hypogonadotropic Hypogonadism - Pipeline by Forendo Pharma Oy, H2 2015
Hypogonadotropic Hypogonadism - Pipeline by Merck & Co., Inc., H2 2015
Hypogonadotropic Hypogonadism - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Hypogonadotropic Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hypogonadotropic Hypogonadism Therapeutics - Recent Pipeline Updates, H2 2015
List of Figures
Number of Products under Development for Hypogonadotropic Hypogonadism, H2 2015
Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report